Table 4

ROC analysis of biomarker combination in Japanese cohort

Case	N	Ctrl	n	BAG4+IL6ST+VWF+CD44+EGFR
Case	N	Ctrl	n	AUC	95% CI	Sens. (%)	95% CI
I	114	All ctrls	386	0.79	0.74 to 0.85	62.3	0.54 to 0.71
II	155	All ctrls	386	0.85	0.81 to 0.89	71.6	0.63 to 0.79
III	147	All ctrls	386	0.88	0.85 to 0.92	77.6	0.68 to 0.85
IV	98	All ctrls	386	0.90	0.86 to 0.95	81.6	0.73 to 0.89
All cancers	514	All ctrls	386	0.86	0.83 to 0.88	73.0	0.68 to 0.78
All cancers	514	Normal	168	0.84	0.81 to 0.87	70.0	0.62 to 0.75
All cancers	514	Polyps	159	0.87	0.85 to 0.90	76.5	0.72 to 0.81
All cancers	514	Colitis	59	0.87	0.84 to 0.90	73.3	0.66 to 0.80

*EGFR and CD44's sialyl Lewis-A and Lewis-X information was added to the 5-protein panel. Coefficients were calculated for All cancers versus All ctrls. All ctrls include normal, polyps and colitis samples.
AUC, area under the curve; BAG4, BAG family molecular chaperone regulator 4; EGFR, epidermal growth factor receptor; IL6ST, interleukin-6 receptor subunit beta; ROC, receiver operating characteristic; Sens., sensitivity at 90% specificity; VWF, von Willebrand factor.